Tetrandrine attenuates left ventricular dysfunction in rats with myocardial infarction

Wu,Youyang; Zhao,Wei; Ye,Fanhao; Huang,Shiwei; Chen,Hao; Zhou,Rui; Jiang,Wenbing

doi:10.3892/etm.2020.9551

Tetrandrine attenuates left ventricular dysfunction in rats with myocardial infarction

Authors:
- Youyang Wu
- Wei Zhao
- Fanhao Ye
- Shiwei Huang
- Hao Chen
- Rui Zhou
- Wenbing Jiang
View Affiliations

Affiliations: Department of Cardiology, The Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Published online on: December 3, 2020 https://doi.org/10.3892/etm.2020.9551
Article Number: 119
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to determine whether tetrandrine could attenuate left ventricular dysfunction and remodeling in rats with myocardial infarction. Sprague‑Dawley rats were randomly divided into six groups (n=5/group) as follows: i) Healthy control group; ii) sham operation group; iii) myocardial infarction model group; iv) myocardial infarction + low‑dose tetrandrine group (10 mg/kg); v) myocardial infarction + medium‑dose tetrandrine group (50 mg/kg); and vi) myocardial infarction + high‑dose tetrandrine group (80 mg/kg). Left ventricular end‑diastolic diameter (LVIDd), left ventricular end‑systolic diameter (LVIDs), ejection fraction (EF%) and left ventricular fractional shortening rate (FS%) were measured using ultrasonography. The pathological changes were observed by hematoxylin and eosin (H&E) staining. Left ventricular tissue section TUNEL staining was also performed. Furthermore, the triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL) and low‑density lipoprotein (LDL) in the arterial blood were examined by biochemical testing. Expression levels of intracellular Ca²⁺ homeostasis‑related proteins including ryanodine receptor calmodulin, CaM‑dependent protein kinase IIδ, protein kinase A, FK506 binding protein 12.6 were measured using western blot analysis. Ultrasonography results showed that in the myocardial infarction model rats, the levels of LVIDd and LVIDs were significantly higher; however, the levels of EF% and FS% were lower compared with those in the sham operation group, which was alleviated by tetrandrine. H&E results showed that tetrandrine alleviated the pathological characteristics of myocardial infarction model rats. Furthermore, tetrandrine significantly inhibited myocardial cell apoptosis in rats with myocardial infarction. Tetrandrine significantly inhibited the levels of TG, TC and LDL and increased the levels of HDL in the arterial blood of rats with myocardial infarction. These findings revealed that tetrandrine could attenuate left ventricular dysfunction in rats with myocardial infarction, which might be associated with intracellular Ca²⁺ homeostasis.

View Figures

View References

1	Liao J, Wang J, Liu Y, Li J and Duan L: Transcriptome sequencing of lncRNA, miRNA, mRNA and interaction network constructing in coronary heart disease. BMC Med Genomics. 12(124)2019.PubMed/NCBI View Article : Google Scholar
2	Agha G, Mendelson MM, Ward-Caviness CK, Joehanes R, Huan TX, Gondalia R, Salfati E, Brody JA, Fiorito G, Bressler J, et al: Blood leukocyte DNA methylation predicts risk of future myocardial infarction and coronary heart disease. Circulation. 140:645–657. 2019.PubMed/NCBI View Article : Google Scholar
3	Zhou M, Bao Y, Li H, Pan Y, Shu L, Xia Z, Wu D, Lam KSL, Vanhoutte PM, Xu A, et al: Deficiency of adipocyte fatty-acid-binding protein alleviates myocardial ischaemia/reperfusion injury and diabetes-induced cardiac dysfunction. Clin Sci (Lond). 129:547–559. 2015.PubMed/NCBI View Article : Google Scholar
4	Thygesen K, Alpert JS and White HD: Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol. 50:2173–2195. 2007.PubMed/NCBI View Article : Google Scholar
5	Winkler A, Jaguś-Jamioła A, Uziębło-Życzkowska B, Orski Z, Krzyżanowski K, Smalc-Stasiak M and Kiliszek M: Predictors of appropriate interventions and mortality in patients with implantable cardioverter-defibrillators. Pol Arch Intern Med. 129:667–672. 2019.PubMed/NCBI View Article : Google Scholar
6	Yuan X, Dou Y, Wu X, Wei Z and Dai Y: Tetrandrine, an agonist of aryl hydrocarbon receptor, reciprocally modulates the activities of STAT3 and STAT5 to suppress Th17 cell differentiation. J Cell Mol Med. 21:2172–2183. 2017.PubMed/NCBI View Article : Google Scholar
7	Kwan CY, Ma FM and Hui SC: Inhibition of endothelium-dependent vascular relaxation by tetrandrine. Life Sci. 64:2391–2400. 1999.PubMed/NCBI View Article : Google Scholar
8	Liou JT, Lin CS, Liao YC, Ho LJ, Yang SP and Lai JH: JNK/AP-1 activation contributes to tetrandrine resistance in T-cell acute lymphoblastic leukaemia. Acta Pharmacol Sin. 38:1171–1183. 2017.PubMed/NCBI View Article : Google Scholar
9	Sakurai Y, Kolokoltsov AA, Chen CC, Tidwell MW, Bauta WE, Klugbauer N, Grimm C, Wahl-Schott C, Biel M and Davey RA: Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science. 347:995–998. 2015.PubMed/NCBI View Article : Google Scholar
10	Zhang J, Yu B, Zhang XQ, Sheng ZF, Li SJ, Wang ZJ, Cui XY, Cui SY and Zhang YH: Tetrandrine, an antihypertensive alkaloid, improves the sleep state of spontaneously hypertensive rats (SHRs). J Ethnopharmacol. 151:729–732. 2014.PubMed/NCBI View Article : Google Scholar
11	Lee YS, Han SH, Lee SH, Kim YG, Park CB, Kang OH, Keum JH, Kim SB, Mun SH, Seo YS, et al: The mechanism of antibacterial activity of tetrandrine against Staphylococcus aureus. Foodborne Pathog Dis. 9:686–691. 2012.PubMed/NCBI View Article : Google Scholar
12	Yu M, Liu T, Chen Y, Li Y and Li W: Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy. J Exp Clin Cancer Res. 37(114)2018.PubMed/NCBI View Article : Google Scholar
13	Westra IM, Oosterhuis D, Groothuis GM and Olinga P: Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs. Toxicol Appl Pharmacol. 274:328–338. 2014.PubMed/NCBI View Article : Google Scholar
14	Ohta T, Yasuda W, Hasegawa A, Ito S and Nakazato Y: Effects of inhibitors for tyrosine kinase and non-selective cation channel on capacitative Ca(2+) entry in rat ileal smooth muscle. Eur J Pharmacol. 387:211–220. 2000.PubMed/NCBI View Article : Google Scholar
15	Shen DF, Tang QZ, Yan L, Zhang Y, Zhu LH, Wang L, Liu C, Bian ZY and Li H: Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling. Br J Pharmacol. 159:970–981. 2010.PubMed/NCBI View Article : Google Scholar
16	Ai J, Gao HH, He SZ, Wang L, Luo DL and Yang BF: Effects of matrine, artemisinin, tetrandrine on cytosolic [Ca²⁺]i in guinea pig ventricular myocytes. Acta Pharmacol Sin. 22:512–515. 2001.PubMed/NCBI
17	Pilz PM, Hamza O, Gidlöf O, Gonçalves IF, Tretter EV, Trojanek S, Abraham D, Heber S, Haller PM, Podesser BK and Kiss A: Remote ischemic perconditioning attenuates adverse cardiac remodeling and preserves left ventricular function in a rat model of reperfused myocardial infarction. Int J Cardiol. 285:72–79. 2019.PubMed/NCBI View Article : Google Scholar
18	Peng L and Zhao Y, Li Y, Zhou Y, Li L, Lei S, Yu S and Zhao Y: Effect of DJ-1 on the neuroprotection of astrocytes subjected to cerebral ischemia/reperfusion injury. J Mol Med (Berl). 97:189–199. 2019.PubMed/NCBI View Article : Google Scholar
19	Zhang TJ, Guo RX, Li X, Wang YW and Li YJ: Tetrandrine cardioprotection in ischemia-reperfusion (I/R) injury via JAK3/STAT3/Hexokinase II. Eur J Pharmacol. 813:153–160. 2017.PubMed/NCBI View Article : Google Scholar
20	Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R and Liu PP: Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation. 115:1398–1407. 2007.PubMed/NCBI View Article : Google Scholar
21	O'Brien F, Venturi E and Sitsapesan R: The ryanodine receptor provides high throughput Ca²⁺-release but is precisely regulated by networks of associated proteins: A focus on proteins relevant to phosphorylation. Biochem Soc Trans. 43:426–433. 2015.PubMed/NCBI View Article : Google Scholar
22	Yano M, Kobayashi S, Kohno M, Doi M, Tokuhisa T, Okuda S, Suetsugu M, Hisaoka T, Obayashi M, Ohkusa T, et al: FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation. 107:477–484. 2003.PubMed/NCBI View Article : Google Scholar
23	Landstrom AP, Dobrev D and Wehrens XHT: Calcium signaling and cardiac arrhythmias. Circ Res. 120:1969–1993. 2017.PubMed/NCBI View Article : Google Scholar
24	Peng W, Shen H, Wu J, Guo W, Pan X, Wang R, Chen SR and Yan N: Structural basis for the gating mechanism of the type 2 ryanodine receptor RyR2. Science. 354(aah5324)2016.PubMed/NCBI View Article : Google Scholar
25	Rocchetti M, Sala L, Dreizehnter L, Crotti L, Sinnecker D, Mura M, Pane LS, Altomare C, Torre E, Mostacciuolo G, et al: Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes. Cardiovascular Res. 113:531–541. 2017.PubMed/NCBI View Article : Google Scholar
26	Fischer TH, Herting J, Tirilomis T, Renner A, Neef S, Toischer K, Ellenberger D, Förster A, Schmitto JD, Gummert J, et al: Ca²⁺/calmodulin-dependent protein kinase II and protein kinase A differentially regulate sarcoplasmic reticulum Ca²⁺ leak in human cardiac pathology. Circulation. 128:970–981. 2013.PubMed/NCBI View Article : Google Scholar
27	Huke S and Bers DM: Ryanodine receptor phosphorylation at Serine. 2030, 2808 and 2814 in rat cardiomyocytes. Biochem Biophys Res Commun. 376:80–85. 2008.PubMed/NCBI View Article : Google Scholar
28	MacMillan D: FK506 binding proteins: Cellular regulators of intracellular Ca²⁺ signalling. Eur J Pharmacol. 700:181–193. 2013.PubMed/NCBI View Article : Google Scholar
29	Luo M and Anderson ME: Mechanisms of altered Ca(2)(+) handling in heart failure. Circ Res. 113:690–708. 2013.PubMed/NCBI View Article : Google Scholar
30	Yamamoto T, Yano M, Xu X, Uchinoumi H, Tateishi H, Mochizuki M, Oda T, Kobayashi S, Ikemoto N and Matsuzaki M: Identification of target domains of the cardiac ryanodine receptor to correct channel disorder in failing hearts. Circulation. 117:762–772. 2008.PubMed/NCBI View Article : Google Scholar
31	Sag CM, Wagner S and Maier LS: Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes. Free Radic Biol Med. 63:338–349. 2013.PubMed/NCBI View Article : Google Scholar
32	Huang T, Xu S, Deo R, Ma A, Li H, Ma K and Gan X: Targeting the Ca(2+)/Calmodulin-dependent protein kinase II by Tetrandrine in human liver cancer cells. Biochem Biophys Res Commun. 508:1227–1232. 2019.PubMed/NCBI View Article : Google Scholar
33	Wang B and Xiao JG: Effect of tetrandrine on free intracellular calcium in cultured calf basilar artery smooth muscle cells. Acta Pharmacol Sin. 23:1121–1126. 2002.PubMed/NCBI
34	Rao MR: Effects of tetrandrine on cardiac and vascular remodeling. Acta Pharmacol Sin. 23:1075–1085. 2002.PubMed/NCBI
35	Pinelli A, Trivulzio S, Brenna S, Galmozzi G and Rossoni G: Pretreatment with tetrandrine has protective effects against isoproterenol-induced myocardial infarction in rabbits. In Vivo. 24:265–270. 2010.PubMed/NCBI
36	Teng G, Svystonyuk D, Mewhort HE, Turnbull JD, Belke DD, Duff HJ and Fedak PWM: Tetrandrine reverses human cardiac myofibroblast activation and myocardial fibrosis. Am J Physiol Heart Circ Physiol. 308:H1564–H1574. 2015.PubMed/NCBI View Article : Google Scholar